Strategic Analysis of Bristol-Myers Squibb's Adjustment of MORAb-202 in the Global Landscape
03 Jul 2024
From a strategic perspective, Bristol-Myers Squibb has been continuously adjusting the priority of its product portfolio in global strategic collaborations, leading to the decision to discontinue MORAb-202. This does not necessarily mean the clinical failure of MORAb-202, but rather that it is of lower priority in the current product mix. Based on available information, MORAb-202 still shows a certain degree of potential.
As for Elahere, one of its main challenges is the limited patient population, as it is only effective for patients with high FRα expression, which accounts for only 35-40% of the ovarian cancer population. Additionally, the safety issues of Elahere, particularly the eye toxicity, which has led to the termination of treatment for one patient due to vision impairment, cannot be ignored. As a result, the FDA has issued a black box warning for Elahere.
In contrast, the data presented at the 2022 ASCO meeting showed that MORAb-202 is also effective for patients with FRα expression below 50% and did not exhibit eye toxicity. Therefore, despite the discontinuation, Daiichi Sankyo remains optimistic about MORAb-202 and plans to prioritize its further development.
However, MORAb-202 also faces challenges. According to the data presented at ASCO, interstitial lung disease/pneumonia is the most common treatment-related adverse event, which is reflected across different dose groups. Although there was only one case of grade 3/4 severity, given the small sample size, the dose optimization and the benefit-risk balance of MORAb-202 still require careful consideration.
In the context of the urgent demand for growth engines, Bristol-Myers Squibb's decision to discontinue MORAb-202, while not directly reflecting its clinical failure, does indicate that the company believes the drug has limited competitiveness. The potential of the FRα-ADC market is vast, but the discontinuation of MORAb-202 further highlights the complexity and uncertainty in this field.
In the FRα-ADC field, the previously perceived "three musketeers" - Elahere, MORAb-202, and STRO-002 - all face their own challenges. The clinical data of STRO-002 did not show the expected advantages, and it also has safety issues such as neutropenia. With the approval of Elahere, the commercial value of STRO-002 has decreased significantly. The discontinuation of MORAb-202 further warns the market that investments and R&D in the FRα-ADC field require a clear-headed approach, objective assessment of early clinical data and significant business development transactions, and adequate preparation to address potential risks and challenges.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Chat with Hiro
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.